Low‐dose rectal diclofenac does not prevent post‐ERCP pancreatitis in low‐ or high‐risk patients

Background and Aim The most common adverse event following an endoscopic retrograde cholangiopancreatography (ERCP) procedure is post‐ERCP pancreatitis (PEP). Rectal nonsteroidal anti‐inflammatory drug (NSAID) administration has shown promise to reduce the risk of PEP in high‐risk patients. However,...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of gastroenterology and hepatology 2020-07, Vol.35 (7), p.1247-1253
Hauptverfasser:	Katoh, Takao, Kawashima, Kousaku, Fukuba, Nobuhiko, Masuda, Shigeto, Kobatake, Hiroko, Masaki, Kousaku, Araki, Yasuhiro, Kawano, Koichiro, Nishi, Katsuhisa, Takenaka, Mamoru, Ishihara, Shunji, Kinoshita, Yoshikazu
Format:	Artikel
Sprache:	eng
Schlagworte:	Diclofenac ERCP Inflammation Nonsteroidal anti-inflammatory drugs Pancreatitis post‐ERCP pancreatitis Rectum
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!